Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January

Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021

Published:2022 Issue:1 Volume:2 Page:
ISSN:2732-494X
Container-title:Antimicrobial Stewardship & Healthcare Epidemiology
language:en
Short-container-title:ASHE

Author:

Graciaa Daniel S.^ORCID,Verkerke Hans P.,Guarner Jeannette,Moldoveanu Ana Maria,Cheedarla Narayanaiah^ORCID,Arthur Connie M.,Maier Cheryl L.^ORCID,Neish Andrew,Auld Sara C.,Campbell Angie^ORCID,Gandhi Neel R.,Roback John D.^ORCID,Shah N. Sarita^ORCID

Abstract

Abstract We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January–March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples are a feasible alternative for rapidly estimating seroprevalence or monitoring trends in infection and vaccination.

Publisher

Cambridge University Press (CUP)

Reference10 articles.

1. Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020

2. Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey

3. 1. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection. World Health Organization website. https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-2020.2. Published May 26, 2020. Accessed September 12, 2022.

4. Adapting Serosurveys for the SARS-CoV-2 Vaccine Era

5. Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Micro blood analysis technology (μBAT): multiplexed analysis of neutrophil phenotype and function from microliter whole blood samples;Lab on a Chip;2024